BR122022018214A2 - Formas cristalinas de um composto farmacêutico - Google Patents

Formas cristalinas de um composto farmacêutico Download PDF

Info

Publication number
BR122022018214A2
BR122022018214A2 BR122022018214-3A BR122022018214A BR122022018214A2 BR 122022018214 A2 BR122022018214 A2 BR 122022018214A2 BR 122022018214 A BR122022018214 A BR 122022018214A BR 122022018214 A2 BR122022018214 A2 BR 122022018214A2
Authority
BR
Brazil
Prior art keywords
compound
crystalline form
disease
ray powder
crystalline
Prior art date
Application number
BR122022018214-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert Hett
Fritz Blatter
Jennifer ROBIN
Kyle LANDSKRONER
Original Assignee
Azafaros B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azafaros B.V. filed Critical Azafaros B.V.
Publication of BR122022018214A2 publication Critical patent/BR122022018214A2/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR122022018214-3A 2020-10-02 2021-10-01 Formas cristalinas de um composto farmacêutico BR122022018214A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20199934.9A EP3978474A1 (en) 2020-10-02 2020-10-02 Crystalline forms of a pharmaceutical compound
EP20199934.9. 2020-10-02
PCT/EP2021/077100 WO2022069709A1 (en) 2020-10-02 2021-10-01 Crystalline forms of a pharmaceutical compound
BR112022018020-9 2021-10-01

Publications (1)

Publication Number Publication Date
BR122022018214A2 true BR122022018214A2 (pt) 2023-05-09

Family

ID=72744696

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122022018214-3A BR122022018214A2 (pt) 2020-10-02 2021-10-01 Formas cristalinas de um composto farmacêutico
BR112022018020-9A BR112022018020B1 (pt) 2020-10-02 2021-10-01 Formas cristalinas de um composto farmacêutico

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022018020-9A BR112022018020B1 (pt) 2020-10-02 2021-10-01 Formas cristalinas de um composto farmacêutico

Country Status (19)

Country Link
US (2) US12116344B2 (cg-RX-API-DMAC10.html)
EP (3) EP3978474A1 (cg-RX-API-DMAC10.html)
JP (2) JP7809655B2 (cg-RX-API-DMAC10.html)
KR (2) KR20240056628A (cg-RX-API-DMAC10.html)
CN (1) CN116390910A (cg-RX-API-DMAC10.html)
AU (2) AU2021353055B2 (cg-RX-API-DMAC10.html)
BR (2) BR122022018214A2 (cg-RX-API-DMAC10.html)
CA (1) CA3193939C (cg-RX-API-DMAC10.html)
CL (1) CL2023000943A1 (cg-RX-API-DMAC10.html)
DK (1) DK4114826T3 (cg-RX-API-DMAC10.html)
ES (1) ES2964105T3 (cg-RX-API-DMAC10.html)
FI (1) FI4114826T3 (cg-RX-API-DMAC10.html)
IL (2) IL316634A (cg-RX-API-DMAC10.html)
MA (1) MA58885B1 (cg-RX-API-DMAC10.html)
MX (1) MX2023003618A (cg-RX-API-DMAC10.html)
PE (1) PE20240138A1 (cg-RX-API-DMAC10.html)
TW (1) TWI912383B (cg-RX-API-DMAC10.html)
WO (1) WO2022069709A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202310184B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978474A1 (en) * 2020-10-02 2022-04-06 Azafaros B.V. Crystalline forms of a pharmaceutical compound
IL314212A (en) * 2022-01-10 2024-09-01 Azafaros B V Treatment of GM2 gangliosidosis
EP4209215A1 (en) * 2022-01-10 2023-07-12 Azafaros B.V. Treatment of gm2 gangliosidosis
AU2025214578A1 (en) 2024-02-01 2026-08-13 Azafaros B.V. Treatment of gm1 gangliosidosis
EP4595964A1 (en) 2024-02-01 2025-08-06 Azafaros B.V. Treatment of gm1 gangliosidosis
EP4678174A1 (en) * 2024-07-11 2026-01-14 Azafaros B.V. Nizubaglustat for use in the treatment of lysosomal storage disorders
WO2026013261A1 (en) * 2024-07-11 2026-01-15 Azafaros B.V. Nizubaglustat for use in the treatment of lysosomal storage disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
US20190195897A1 (en) * 2015-06-24 2019-06-27 Universiteit Leiden Glycosylated metabolites
EP3978474A1 (en) * 2020-10-02 2022-04-06 Azafaros B.V. Crystalline forms of a pharmaceutical compound

Also Published As

Publication number Publication date
WO2022069709A1 (en) 2022-04-07
JP7809655B2 (ja) 2026-02-02
AU2021353055B2 (en) 2022-10-06
TWI912383B (zh) 2026-01-21
TW202229236A (zh) 2022-08-01
EP3978474A1 (en) 2022-04-06
MX2023003618A (es) 2023-07-14
AU2022291486A1 (en) 2023-02-02
ES2964105T3 (es) 2024-04-04
FI4114826T3 (fi) 2023-11-21
IL301882B1 (en) 2024-12-01
EP4114826A1 (en) 2023-01-11
CL2023000943A1 (es) 2023-09-29
DK4114826T3 (da) 2023-11-13
PE20240138A1 (es) 2024-01-30
NZ798892A (en) 2023-09-29
IL301882A (en) 2023-06-01
CN116390910A (zh) 2023-07-04
KR20240056628A (ko) 2024-04-30
BR112022018020A2 (pt) 2023-04-18
JP2024054192A (ja) 2024-04-16
IL301882B2 (en) 2025-04-01
BR112022018020B1 (pt) 2023-12-26
CA3193939C (en) 2024-02-20
EP4295847A3 (en) 2024-02-28
US20230391724A1 (en) 2023-12-07
ZA202310184B (en) 2024-01-31
AU2021353055A1 (en) 2022-09-15
KR20230078798A (ko) 2023-06-02
US12116344B2 (en) 2024-10-15
AU2022291486B2 (en) 2024-07-25
US20250059137A1 (en) 2025-02-20
KR102659466B1 (ko) 2024-04-19
US20240287001A9 (en) 2024-08-29
JP2023524169A (ja) 2023-06-08
CA3193939A1 (en) 2022-04-07
IL316634A (en) 2024-12-01
EP4295847A2 (en) 2023-12-27
MA58885B1 (fr) 2023-11-30
EP4114826B1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
US12116344B2 (en) Crystalline forms of a pharmaceutical compound
US20250120958A1 (en) Treatment of GM2 Gangliosidosis
US11834431B2 (en) Crystals of cyclic amine derivative and pharmaceutical use thereof
NZ798892B2 (en) Crystalline forms of a pharmaceutical compound
HK40087007A (en) Crystalline forms of a pharmaceutical compound
HK40087007B (en) Crystalline forms of a pharmaceutical compound
EA045552B1 (ru) Кристаллические формы фармацевтического соединения
EA052826B1 (ru) Кристаллические формы фармацевтического соединения

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]